AKT1 and Huntington disease: Indeed, both verities were proven with the current DMF treatment in the striatum of HD rats to align with the activation/phosphorylation of AKT in neurodegenerative models (Cuadrado et al., 2018; Abd El-Fatah et al., 2021); however, this is the first report to verify the stimulatory effect of the drug on mTOR.